Trial of a new tricuspid valve replacement device
Part of Heart & circulation clinical trials.
This trial tests a new catheter-based device to replace your tricuspid valve without open-heart surgery. It's for people with severe tricuspid regurgitation who are at high risk for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 84 years old.
- You have severe tricuspid valve leakage (grade 3 or higher) based on an echocardiogram.
- You have symptoms of heart failure, like shortness of breath or swelling, that limit your daily activities.
- Your heart's main pumping chamber is working at least 30% of normal.
- You are considered too high risk for open-heart surgery.
- Your vein and heart valve anatomy are suitable for the procedure (checked by a CT scan).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new, catheter-based procedure to treat moderate-to-severe leaking of the tricuspid valve (a heart valve on the right side). It’s for people who are high surgical risk and might benefit from replacing the valve without open-heart surgery.
This trial tests a new device called Laplace TTVR to replace a leaky tricuspid valve in the heart without open surgery. It is for people with severe symptoms despite medical treatment.
This trial tests a catheter-based procedure (done through the blood vessels) to repair a severely leaky tricuspid valve. It may help people with symptoms or past hospitalizations from tricuspid valve leakage who are higher-risk for standard surgery.
This study tests a new, less invasive way to replace the tricuspid valve (the valve between the right upper and lower heart chambers) in people with severe leakage. The valve is delivered through a vein in the neck or leg, avoiding open-heart surgery.
This trial tests a new catheter-based procedure that replaces the tricuspid valve to reduce severe valve leaking. It may help people who still have symptoms despite heart medicines, but only if their heart shape and other health details fit the device requirements.
This trial tests the DragonFly-T system to improve symptoms and heart function in people with severe tricuspid regurgitation (a leaky heart valve) using a catheter-based repair. It may help reduce valve leak–related symptoms when standard medication isn’t enough and surgery risk is higher.
Hear when a new Tricuspid Regurgitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.